Literature DB >> 16682281

Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH: diagnostic and prognostic relevance.

I G H Schmidt-Wolf1, A Glasmacher, C Hahn-Ast, A Jüttner, T Schnurr, F Cremer, T Moehler, H Goldschmidt, B Busert, R Schubert, G Schwanitz.   

Abstract

The study described the molecular cytogenetic characterization of myeloma cells in 130 patients via interphase fluorescence in situ hybridization. Nine repetitive DNA probes (for chromosomes 3, 7, 9, 11, 15, 17, 18, X, and Y) as well as seven single-copy DNA probes (for chromosomes 13, 17, 21, and two each for chromosomes 5 and 22) were used for the hybridizations. Using this panel of probes, we were able to show aberrations in 86% of patients. Most of them had one to three aberrations. There was a distinct correlation between the number of aberrations per patient and the tumor stage. Thus, the proportion of patients with 8-12 aberrations increased from 16% in stage II to 26% in stage III. There were marked differences among the chromosomes with respect to the prevalence of genomic losses and gains and deletions of gene loci. Chromosomes 3, 5, 7, 9, 11, 15, and 21 showed a preference for genomic gains. Losses were most often found for chromosomes 13 and 17 (locus specific) as well as for the X and Y chromosomes. The frequency of monosomies and trisomies were approximately the same for chromosomes 15 and 18, which indicates a skewed pattern of distribution. We found two specific aberrations that caused distinct changes in the survival rates of the patients: deletion 13q14 (28% of patients) and translocation of the IGH locus 14q32 (79% of 39 patients who were analyzed separately). The results obtained in this study yielded data of extremely relevant prognostic value.

Entities:  

Mesh:

Year:  2006        PMID: 16682281     DOI: 10.1016/j.cancergencyto.2005.10.016

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  9 in total

1.  Fluorescence in situ hybridization analysis of chromosome aberrations in 60 Chinese patients with multiple myeloma.

Authors:  Xiao Gao; Chunming Li; Run Zhang; Ruifang Yang; Xiaoyan Qu; Hairong Qiu; Jiaren Xu; Hua Lu; Jianyong Li; Lijuan Chen
Journal:  Med Oncol       Date:  2011-05-25       Impact factor: 3.064

2.  The RBCC gene RFP2 (Leu5) encodes a novel transmembrane E3 ubiquitin ligase involved in ERAD.

Authors:  Mikael Lerner; Martin Corcoran; Diana Cepeda; Michael L Nielsen; Roman Zubarev; Fredrik Pontén; Mathias Uhlén; Sophia Hober; Dan Grandér; Olle Sangfelt
Journal:  Mol Biol Cell       Date:  2007-02-21       Impact factor: 4.138

3.  Clinical utility of FISH analysis in addition to G-banded karyotype in hematologic malignancies and proposal of a practical approach.

Authors:  Won Kyung Kwon; Jin Young Lee; Yeung Chul Mun; Chu Myong Seong; Wha Soon Chung; Jungwon Huh
Journal:  Korean J Hematol       Date:  2010-09-30

4.  IRF4 promotes cell proliferation by JNK pathway in multiple myeloma.

Authors:  Sensen Zhang; Jiaren Xu; Shuang Wu; Rong Wang; Xiaoyan Qu; Wenjun Yu; Jiangyong Li; Lijuan Chen
Journal:  Med Oncol       Date:  2013-05-12       Impact factor: 3.064

5.  Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo.

Authors:  Benedetto Bruno; Marcello Rotta; Francesca Patriarca; Daniele Mattei; Bernardino Allione; Fabrizio Carnevale-Schianca; Roberto Sorasio; Alessandro Rambaldi; Marco Casini; Matteo Parma; Pasqua Bavaro; Francesco Onida; Alessandro Busca; Luca Castagna; Edoardo Benedetti; Anna Paola Iori; Luisa Giaccone; Antonio Palumbo; Paolo Corradini; Renato Fanin; David Maloney; Rainer Storb; Ileana Baldi; Umberto Ricardi; Mario Boccadoro
Journal:  Blood       Date:  2008-12-08       Impact factor: 22.113

6.  Impact of genetic abnormalities on the prognoses and clinical parameters of patients with multiple myeloma.

Authors:  Dong Wook Jekarl; Chang-Ki Min; Ahlm Kwon; Hyunjung Kim; Hyojin Chae; Myungshin Kim; Jihyang Lim; Yonggoo Kim; Kyungja Han
Journal:  Ann Lab Med       Date:  2013-06-24       Impact factor: 3.464

7.  Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012.

Authors:  Vânia Tietsche de Moraes Hungria; Edvan de Queiroz Crusoe; Adriana Alvarez Quero; Manuella Sampaio; Angelo Maiolino; Wanderley Marques Bernardo
Journal:  Rev Bras Hematol Hemoter       Date:  2013

8.  Conventional and molecular cytogenetic analyses in Turkish patients with multiple myeloma.

Authors:  Beyhan Aras Durak; Olga Meltem Akay; Gülçin Sungar; Güney Bademci; Vahap Aslan; Jülide Caferler; Muhsin Ozdemir; Oğuz Cilingir; Sevilhan Artan; Zafer Gülbaş
Journal:  Turk J Haematol       Date:  2012-06-15       Impact factor: 1.831

9.  The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population.

Authors:  Wenjun Yu; Rui Guo; Xiaoyan Qu; Hairong Qiu; Jianyong Li; Run Zhang; Lijuan Chen
Journal:  Onco Targets Ther       Date:  2016-01-12       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.